At Texas Retina Associates, we remain committed to examining new options that are ethical, based on a solid science platform and provide minimal risks to our patients. Our Plano research team is currently enrolling patients for two new studies:

Diabetic Macular Edema (DME)
Study Title: Glimmer
A Phase III, two-year study for patients 18 years old or older with type I or II diabetes and treatment naïve DME. Their HbA1c must be 12% or less, vision between 20/25 and 20/320, and a central OCT thickness of 320 microns or greater. Subjects enrolled in the study will be randomized to one of two groups. Group A will receive the study drug, KSI-301, per an individualized study treatment regimen after three monthly loading doses. Group B will receive aflibercept every eight weeks after five monthly loading doses. Sham injections will be performed when a study treatment is not required to protect masking. Study duration is two years.
Principal Investigator: Lori E. Coors, MD

For more information, please contact Study Coordinator Tara Keesling at 214-706-0438. For additional trial details, please refer to the study on ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT04603937.


Retinal Vein Occlusion (RVO)
Branch Retinal Vein Occlusion (BRVO) – Central Retinal Vein Occlusion (CRVO) – Hemiretinal Vein Occlusion (HRVO)
Study Title: Beacon
A Phase III, one-year study for patients 18 years old or older with treatment naïve visual impairment secondary to RVO (BRVO/CRVO/HRVO). The subject’s vision must be between 20/25 and 20/320 with a central OCT thickness of 320 microns or greater. Subjects enrolled in the study will be randomized to one of two groups. Group A will receive the study drug, KSI-301, every eight weeks after two loading doses, followed by a six-month individualized treatment regimen. Group B will receive aflibercept monthly aflibercept for six doses followed by a six-month individualized treatment regimen. Sham injections will be performed when a study treatment is not required to protect masking. Study duration is one year.
Principal Investigator: Robert C. Wang, MD

For more information, please contact Study Coordinator Tara Keesling at 214-706-0438. For additional trial details, please refer to the study on ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT04592419.

As always, please know that we will take the time to make sure participants are not only fully informed, but truly understand what it means for them to participate in any of our clinical trials.

You can access a full listing of clinical trials offered at Texas Retina Associates here.